Portal de investigação
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Wei, FF
- Pellicori, P
- González, A
- Mariottoni, B
- An, DW
- Verdonschot, JAJ
- Liu, C
- Ahmed, FZ
- Petutschnigg, J
- Rossignol, P
- Heymans, S
- Cuthbert, J
- Girerd, N
- Clark, AL
- Li, Y
- Nawrot, TS
- Diez, J
- Zannad, F
- Cleland, JGF
- Staessen, JA
- HOMAGE Investigators
Unidades de investigação
Abstract
None of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to usual treatment with or without spironolactone (25-50 mg/day). The current substudy included 113 controls and 114 patients assigned spironolactone, who all completed the incremental shuttle walk test at baseline and months 1 and 9. Quality of life (QoL) was assessed by EQ5D questionnaire. Between-group differences (spironolactone minus control [Delta s]) were analyzed by repeated measures ANOVA with adjustment for baseline and, if appropriate, additionally for sex, age and body mass index. Delta s in the pre-exercise systolic/diastolic BP were -8.00 mm Hg (95% CI, -11.6 to -4.43)/-0.85 mm Hg (-2.96 to 1.26) at month 1 and -9.58 mm Hg (-14.0 to -5.19)/-3.84 mm Hg (-6.22 to -1.47) at month 9. Delta s in the post-exercise systolic/diastolic BP were -8.08 mm Hg (-14.2 to -2.01)/-2.07 mm Hg (-5.79 to 1.65) and -13.3 mm Hg (-19.9 to -6.75)/-4.62 mm Hg (-8.07 to -1.17), respectively. For completed shuttles, Delta s at months 1 and 9 were 2.15 (-0.10 to 4.40) and 2.49 (-0.79 to 5.67), respectively. Delta s in QoL were not significant. The correlations between the exercise-induced BP increases and the number of completed shuttles were similar in both groups. In conclusion, in patients at increased risk of developing HF, spironolactone reduced the pre- and post-exercise BP, but did not improve exercise capacity or QoL.
Dados da publicação
- ISSN/ISSNe:
- 1348-4214, 0916-9636
- Tipo:
- Article
- Páginas:
- 3225-3236
- Link para outro recurso:
- www.scopus.com
Hypertension Research Nature Publishing Group
Documentos
- Não há documentos
Filiações
Keywords
- Coronary heart disease; Exercise capacity; Incremental shuttle walk test; Heart failure; Spironolactone
Campos de estudo
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023
Citar a publicação
Wei FF,Pellicori P,Ferreira JP,González A,Mariottoni B,An DW,Verdonschot J,Liu C,Ahmed FZ,Petutschnigg J,Rossignol P,Heymans S,Cuthbert J,Girerd N,Clark AL,Li Y,Nawrot TS,Diez J,Zannad F,Cleland JGF,Staessen JA,HOMAGE I. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial. Hypertens. Res. 2024. 47. (11):p. 3225-3236. IF:5,400. (2).
